Literature DB >> 1992358

Young-onset Parkinson's disease: a clinical review.

L I Golbe1.   

Abstract

Young-onset Parkinson's disease (YOPD) is arbitrarily defined as that which produces initial symptoms between the ages of 21 and 39, inclusive. The special problems and concerns of the patient with YOPD present as much of a challenge and opportunity for the clinician as the disease itself does for the researcher. In contrast to juvenile parkinsonism, which is a heterogeneous group of clinicopathologic entities presenting (also arbitrarily) before age 21, YOPD appears to be the same nosologic entity as older-onset PD. It comprises approximately 5% of referral populations in Western countries and about 10% in Japan. Its annual incidence relative to the population at risk is about 1/10 that of PD at age sixty. YOPD tends to have more gradual progression of parkinsonian signs and symptoms, earlier appearance of levodopa-related dyskinesias and levodopa-dose-related motor fluctuations, and frequent presence of dystonia as an early or presenting sign. Studies conflict with regard to the suspected greater familial frequency and lesser frequency of dementia than in older-onset PD.

Entities:  

Mesh:

Year:  1991        PMID: 1992358     DOI: 10.1212/wnl.41.2_part_1.168

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  25 in total

1.  The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years.

Authors:  M A Hely; J G Morris; R Traficante; W G Reid; D J O'Sullivan; P M Williamson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

Review 2.  Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.

Authors:  Teus van Laar
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 3.  Juvenile parkinsonism: epidemiology, diagnosis and treatment.

Authors:  Teri R Thomsen; Robert L Rodnitzky
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

4.  Cost of illness and its predictors for Parkinson's disease in Germany.

Authors:  Annika E Spottke; Martin Reuter; Olaf Machat; Bernhard Bornschein; Sonja von Campenhausen; Karin Berger; Rudolf Koehne-Volland; Jürgen Rieke; Alexander Simonow; Dirk Brandstaedter; Uwe Siebert; Wolfgang H Oertel; Gudrun Ulm; Richard Dodel
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Dyskinetic Parkinson's disease patients demonstrate motor abnormalities off medication.

Authors:  James K R Stevenson; Pouria Talebifard; Edna Ty; Meeko M K Oishi; Martin J McKeown
Journal:  Exp Brain Res       Date:  2011-08-30       Impact factor: 1.972

Review 6.  When should levodopa therapy be initiated in patients with Parkinson's disease?

Authors:  Irene A C Halkias; Ihtsham Haq; Zhigao Huang; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 7.  Dystonia in Parkinson's disease.

Authors:  Eduardo Tolosa; Yaroslau Compta
Journal:  J Neurol       Date:  2006-12       Impact factor: 4.849

8.  Nanocarrier for the transdermal delivery of an antiparkinsonian drug.

Authors:  Adnan Azeem; Farhan J Ahmad; Roop K Khar; Sushama Talegaonkar
Journal:  AAPS PharmSciTech       Date:  2009-09-09       Impact factor: 3.246

9.  Parkinson's disease: genetics and beyond.

Authors:  N N Inamdar; D K Arulmozhi; A Tandon; S L Bodhankar
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

10.  Utility and implications of exome sequencing in early-onset Parkinson's disease.

Authors:  Joanne Trinh; Katja Lohmann; Hauke Baumann; Alexander Balck; Max Borsche; Norbert Brüggemann; Leon Dure; Marissa Dean; Jens Volkmann; Sinem Tunc; Jannik Prasuhn; Heike Pawlack; Sophie Imhoff; Christina M Lill; Meike Kasten; Peter Bauer; Arndt Rolfs; Christine Klein
Journal:  Mov Disord       Date:  2018-12-10       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.